Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tudorza

- PMLiVE

Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD

The common inflammatory skin disease affects over 4% of adults in the EU

- PMLiVE

Almirall set to participate in Innovative Medicines Initiative’s FACILITATE project

The project aims to return clinical trial data to participants, readying it for reuse in future research

- PMLiVE

Almirall granted EMA approval for lebrikizumab in atopic dermatitis

The Marketing Authorization Application is based on three pivotal phase 3 studies

- PMLiVE

Almirall launches call on AlmirallShare to find innovative therapies for skin diseases

Since its launch, the R&D platform has received over 560 proposals from over 50 countries

- PMLiVE

Happify Health and Almirall launch Claro to support psoriasis patients

The digital wellness app is now available to those with the condition living in the UK, Spain and Italy

- PMLiVE

Almirall shares positive topline results from atopic dermatitis trials

The company plans to submit a Marketing Authorisation Application to the EMA later this year

- PMLiVE

Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month

The global event will take place annually on 24 May to increase awareness of skin cancer

- PMLiVE

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

- PMLiVE

Almirall and Inserm Transfert to develop innovative vitiligo treatments

Vitiligo is a chronic skin condition that affects patients worldwide

- PMLiVE

Lebrikizumab achieves skin clearance in pivotal phase 3 atopic dermatitis trials

More than 50% of patients with moderate-to-severe atopic dermatitis experienced at least a 75% reduction in disease severity at 16 weeks

- PMLiVE

Almirall and IRB Barcelona announce new research collaboration

The two companies will work together to discover new therapies for chronic skin diseases

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

Wilmington Healthcare

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links